Poly(trehalose) Nanoparticles Prevent Amyloid Aggregation and Suppress Polyglutamine Aggregation in a Huntington's Disease Model Mouse.

Debnath K, Pradhan N, Singh BK, Jana NR, Jana NR.

ACS Appl Mater Interfaces. 2017 Jul 19;9(28):24126-24139. doi: 10.1021/acsami.7b06510. Epub 2017 Jul 3.

Regenerative medicine in Huntington's disease: strengths and weaknesses of preclinical studies.

Tartaglione AM, Popoli P, Calamandrei G.

Neurosci Biobehav Rev. 2017 Feb 18. pii: S0149-7634(16)30778-3. doi: 10.1016/j.neubiorev.2017.02.017. [Epub ahead of print] Review.

Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.

Wu D, Faria AV, Younes L, Mori S, Brown T, Johnson H, Paulsen JS, Ross CA, Miller MI; PREDICT-HD Investigators and Coordinators of the Huntington Study Group..

Hum Brain Mapp. 2017 Oct;38(10):5035-5050. doi: 10.1002/hbm.23713. Epub 2017 Jun 28.

Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease.

Sánchez-Castañeda C, de Pasquale F, Caravasso CF, Marano M, Maffi S, Migliore S, Sabatini U, Squitieri F.

CNS Neurosci Ther. 2017 Jun;23(6):488-497. doi: 10.1111/cns.12701. Epub 2017 May 2.

Treadmill exercise delays the onset of non-motor behaviors and striatal pathology in the CAG(140) knock-in mouse model of Huntington's disease.

Stefanko DP, Shah VD, Yamasaki WK, Petzinger GM, Jakowec MW.

Neurobiol Dis. 2017 May 11;105:15-32. doi: 10.1016/j.nbd.2017.05.004. [Epub ahead of print]

Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?

Morea V, Bidollari E, Colotti G, Fiorillo A, Rosati J, De Filippis L, Squitieri F, Ilari A.

Amino Acids. 2017 Apr 10. doi: 10.1007/s00726-017-2417-2. [Epub ahead of print] Review.

Reduced striato-cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients.

Garcia-Gorro C, de Diego-Balaguer R, Martínez-Horta S, Pérez-Pérez J, Kulisevsky J, Rodríguez-Dechicha N, Vaquer I, Subira S, Calopa M, Muñoz E, Santacruz P, Ruiz-Idiago J, Mareca C, Caballol N, Camar

Hum Brain Mapp. 2017 Oct 8. doi: 10.1002/hbm.23813. [Epub ahead of print]

Trojan triplets: RNA-based pathomechanisms for muscle dysfunction in Huntington's disease.

Skov M, Dirksen RT.

J Gen Physiol. 2017 Jan;149(1):49-53. doi: 10.1085/jgp.201611728. No abstract available.

Localization of neuroglobin in the brain of R6/2 mouse model of Huntington's disease.

Cardinale A, Fusco FR, Paldino E, Giampà C, Marino M, Nuzzo MT, D'Angelo V, Laurenti D, Straccia G, Fasano D, Sarnataro D, Squillaro T, Paladino S, Melone MAB.

Neurol Sci. 2017 Nov 3. doi: 10.1007/s10072-017-3168-2. [Epub ahead of print]

Functional impairment of precerebral arteries in Huntington disease.

Kobal J, Cankar K, Pretnar J, Zaletel M, Kobal L, Teran N, Melik Z.

J Neurol Sci. 2017 Jan 15;372:363-368. doi: 10.1016/j.jns.2016.10.033.

Xeroderma pigmentosum complementation group F: A rare cause of cerebellar ataxia with chorea.

Carré G, Marelli C, Anheim M, Geny C, Renaud M, Rezvani HR, Koenig M, Guissart C, Tranchant C.

J Neurol Sci. 2017 May 15;376:198-201. doi: 10.1016/j.jns.2017.03.021. Epub 2017 Mar 16.

Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.Htt(Q111/+) model of Huntington's disease.

Bragg RM, Coffey SR, Weston RM, Ament SA, Cantle JP, Minnig S, Funk CC, Shuttleworth DD, Woods EL, Sullivan BR, Jones L, Glickenhaus A, Anderson JS, Anderson MD, Dunnett SB, Wheeler VC, MacDonald ME,

Sci Rep. 2017 Feb 8;7:41570. doi: 10.1038/srep41570.

Bilateral chorea-ballism and diabetic ketoacidosis as the initial presentation of a case with maternally inherited diabetes and deafness.

Ko TH, Lee HH, Hsieh AT, Hu CJ, Chen CC.

Acta Diabetol. 2017 Mar 30. doi: 10.1007/s00592-017-0982-1. [Epub ahead of print] No abstract available.

Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.

Velusamy T, Panneerselvam AS, Purushottam M, Anusuyadevi M, Pal PK, Jain S, Essa MM, Guillemin GJ, Kandasamy M.

Oxid Med Cell Longev. 2017;2017:3279061. doi: 10.1155/2017/3279061. Epub 2017 Jan 12. Review.

An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease.

Underwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J, Jones PS, Rowe JB, Rubinsztein DC, Barker RA.

J Neurol. 2017 Oct 26. doi: 10.1007/s00415-017-8647-0. [Epub ahead of print]